Literature DB >> 30529733

Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups.

Barbara J Turner1, Chen-Pin Wang2, Trisha V Melhado3, Raudel Bobadilla3, Mamta K Jain4, Amit G Singal4.   

Abstract

BACKGROUND & AIMS: Advanced liver disease, which includes fibrosis and cirrhosis, has been reported to be more prevalent in Hispanics patients at the time of diagnosis of chronic hepatitis C virus (HCV) infection than non-Hispanic black or non-Hispanic white patients. We performed a propensity score-matched analysis to determine whether metabolic risk factors contribute to this disparity.
METHODS: We collected data from persons with 748 HCV infection (22% Hispanic, 53% non-Hispanic black, and 26% non-Hispanic white; 23% with advanced liver disease), born from 1945 through 1965, diagnosed at 6 health care systems in Texas. Advanced liver disease was defined as a FIB-4 index score above 3.25. We examined the association between advanced liver disease and race or ethnicity, metabolic risk (based on diabetes mellitus and body mass index [BMI]) and heavy alcohol use in propensity score-matched analyses.
RESULTS: In propensity-score matched models, among those who were obese (BMI ≥30) with a diagnosis of diabetes, the adjusted odds ratio of advanced liver disease for Hispanics vs non-Hispanic black was 7.89 (95% CI, 3.66-17.01) and adjusted odds ratio = 12.49 (95% CI, 3.24-48.18) for Hispanic vs non-Hispanic white patients (both P < .001).
CONCLUSIONS: HCV-infected Hispanics with obesity and diabetes have a far higher risk for advanced liver disease than other racial or ethnic groups. These findings highlight the need for HCV treatment and management of probable concurrent fatty liver disease. Even after we accounted for metabolic risk factors, Hispanics were still at higher risk for advanced liver disease, indicating the potential involvement of other factors such as genetic variants.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Advanced Liver Disease; Chronic Hepatitis C; Health Disparity; Metabolic Syndrome

Year:  2018        PMID: 30529733     DOI: 10.1016/j.cgh.2018.11.059

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  5 in total

1.  The HCV Treatment Cascade: Race Is a Factor to Consider.

Authors:  Maya Balakrishnan; Fasiha Kanwal
Journal:  J Gen Intern Med       Date:  2019-10       Impact factor: 5.128

2.  Association of Genetic Polymorphisms With Hepatitis C Virus-related Liver Cirrhosis in Japan.

Authors:  Shinya Kamimura; Akinori Tamura; Tomotaka Ishii; Tatsuo Kanda; Mitsuhiko Moriyama
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

3.  The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods.

Authors:  Maurizio Soresi; Daniela Cabibi; Rosaria V Giglio; Stefania Martorana; Giuseppina Guercio; Rossana Porcasi; Antonino Terranova; Luigi A Lazzaro; Maria R Emma; Giuseppa Augello; Melchiorre Cervello; Gianni Pantuso; Giuseppe Montalto; Lydia Giannitrapani
Journal:  Biomed Res Int       Date:  2020-04-26       Impact factor: 3.411

4.  Long-term impact of certain coexisting extrahepatic unisystem and multisystem manifestations on trends in incidence of liver cirrhosis in treatment-naïve patients with chronic hepatitis C: A nested case-control study.

Authors:  Chun-Hsiang Wang; Shih-Fang Ou; Yuan-Tsung Tseng
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

5.  Funding of Hispanic/Latino Health-Related Research by the National Institutes of Health: An Analysis of the Portfolio of Research Program Grants on Six Health Topic Areas.

Authors:  M Larissa Avilés-Santa; Laura Hsu; Tram Kim Lam; S Sonia Arteaga; Ligia Artiles; Sean Coady; Lawton S Cooper; Jennifer Curry; Patrice Desvigne-Nickens; Holly L Nicastro; Adelaida Rosario
Journal:  Front Public Health       Date:  2020-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.